X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA LUPIN LTD PLETHICO PHARMA/
LUPIN LTD
 
P/E (TTM) x -1.1 28.3 - View Chart
P/BV x 0.0 3.0 0.6% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PLETHICO PHARMA   LUPIN LTD
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
LUPIN LTD
Mar-18
PLETHICO PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs3951,465 27.0%   
Low Rs31727 4.3%   
Sales per share (Unadj.) Rs604.4349.6 172.9%  
Earnings per share (Unadj.) Rs32.55.6 584.4%  
Cash flow per share (Unadj.) Rs51.329.6 173.5%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs473.6300.3 157.7%  
Shares outstanding (eoy) m34.08452.08 7.5%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x0.43.1 11.2%   
Avg P/E ratio x6.6197.2 3.3%  
P/CF ratio (eoy) x4.237.1 11.2%  
Price / Book Value ratio x0.53.6 12.3%  
Dividend payout %090.0 0.0%   
Avg Mkt Cap Rs m7,262495,502 1.5%   
No. of employees `000NA17.0 0.0%   
Total wages/salary Rs m1,59628,647 5.6%   
Avg. sales/employee Rs ThNM9,273.6-  
Avg. wages/employee Rs ThNM1,681.0-  
Avg. net profit/employee Rs ThNM147.4-  
INCOME DATA
Net Sales Rs m20,598158,042 13.0%  
Other income Rs m3861,504 25.7%   
Total revenues Rs m20,984159,545 13.2%   
Gross profit Rs m2,81831,475 9.0%  
Depreciation Rs m64210,859 5.9%   
Interest Rs m1,5932,044 78.0%   
Profit before tax Rs m96920,076 4.8%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m-1382,885 -4.8%   
Profit after tax Rs m1,1072,513 44.1%  
Gross profit margin %13.719.9 68.7%  
Effective tax rate %-14.314.4 -99.4%   
Net profit margin %5.41.6 338.0%  
BALANCE SHEET DATA
Current assets Rs m18,877122,095 15.5%   
Current liabilities Rs m11,89650,956 23.3%   
Net working cap to sales %33.945.0 75.3%  
Current ratio x1.62.4 66.2%  
Inventory Days Days3685 42.5%  
Debtors Days Days198120 165.0%  
Net fixed assets Rs m9,861129,876 7.6%   
Share capital Rs m341904 37.7%   
"Free" reserves Rs m12,331134,866 9.1%   
Net worth Rs m16,139135,771 11.9%   
Long term debt Rs m4,70664,245 7.3%   
Total assets Rs m33,146263,054 12.6%  
Interest coverage x1.610.8 14.9%   
Debt to equity ratio x0.30.5 61.6%  
Sales to assets ratio x0.60.6 103.4%   
Return on assets %8.11.7 470.3%  
Return on equity %6.91.9 370.6%  
Return on capital %12.33.7 330.4%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40253,141 8.3%   
Fx outflow Rs m3,18419,335 16.5%   
Net fx Rs m1,21933,807 3.6%   
CASH FLOW
From Operations Rs m2,43717,512 13.9%  
From Investments Rs m-6,265-14,073 44.5%  
From Financial Activity Rs m2,490-14,921 -16.7%  
Net Cashflow Rs m-1,337-11,482 11.6%  

Share Holding

Indian Promoters % 82.7 46.6 177.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 4.3 11.3 38.1%  
FIIs % 5.5 31.9 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 10.1 74.3%  
Shareholders   10,665 98,259 10.9%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Lower; FMCG & IT Stocks Witness Losses(Closing)

After opening the day on a positive note today, Indian share markets witnessed losses thereafter and ended their trading session marginally lower.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS